Next Potential Big ADC Player? Korean Firms Take It Up A Notch
Most Assets Still Early Stage
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
You may also be interested in...
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.